CJC-1295 vs GDF-11
Head-to-head comparison of CJC-1295 and GDF-11 for research applications. Both peptides are studied for Anti-Aging, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Cjc 1295 | Gdf 11 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Anti-Aging / Regenerative |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous growth hormone, which in turn increases IGF-1 levels. | GDF-11 signals through activin type II receptors (ActRIIA and ActRIIB) and downstream SMAD2/3 transcription factors. |
| Evidence Rating | D — Preclinical | D — Preclinical / Conflicting Data |
| Clinical Status | Research-only / Not approved for human use | Preclinical only. No human clinical trials. Highly controversial preclinical results. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | No human safety data exists; Shares 90% homology with myostatin; may cause muscle wasting at high doses |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~12.5 kDa (mature dimer) |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | N/A |
Overview
CJC-1295 and GDF-11 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
GDF-11 — Mechanism & Evidence
GDF-11 is a member of the TGF-β superfamily that gained widespread attention after a 2013 Harvard study suggested it could reverse age-related cardiac hypertrophy when young blood was transfused into old mice (parabiosis). Subsequent research has been highly controversial, with conflicting reports on whether GDF-11 levels decline with age and whether supplementation is beneficial or harmful. The "young blood factor" narrative has been significantly challenged by replication failures and contradictory data.
Key claims: Reverses age-related cardiac hypertrophy; Promotes neurogenesis and brain rejuvenation; Improves muscle regeneration.
Shared Research Applications
Both peptides are studied for: Anti-Aging.
CJC-1295 is also researched for: Body Composition.
GDF-11 is also researched for: Regenerative Medicine.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
GDF-11: No human safety data exists Shares 90% homology with myostatin; may cause muscle wasting at high doses TGF-β superfamily members have complex dose-dependent effects that can be beneficial or harmful
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe